Navigation Links
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
Date:1/9/2009

DUBLIN, Ireland, January 9 /PRNewswire/ -- Azur Pharma Limited ("Azur Pharma") today announced that it licensed the exclusive U.S. marketing rights for Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R) (carbidopa-levodopa orally disintegrating tablets), Kemstro(TM) (baclofen orally disintegrating tablets) and Fluxid(TM) (famotidine orally disintegrating tablets) from UCB (Euronext: UCB). Financial terms were not disclosed.

Niravam, Parcopa and Kemstro are central nervous system ("CNS") products. Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenia drug treatments. FazaClo is supplied as an innovative orally disintegrating tablet that uses proprietary formulation technologies licensed from CIMA Labs Inc. ("CIMA"), a subsidiary of Cephalon Inc (NASDAQ: CEPH).

Mr Seamus Mulligan, Chairman and Chief Executive of Azur stated, "We are pleased to add these valuable products to our portfolio. In particular, Niravam, Parcopa and Kemstro represent a broadening of our CNS franchise and are consistent with our approach of improving our products through the application of value added drug delivery technologies."

Niravam and Parcopa have been commercially available in the U.S. since 2005 and 2004, respectively. There is one approved generic competitor to Parcopa. Two ANDAs to Niravam have been filed with the FDA. Kemstro and Fluxid are both FDA approved but not yet commercially available in the U.S.

About Azur Pharma

Azur is a privately held pharmaceutical company dedicated to enhancing patients' lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur's strategy is to identify, evaluate, selectively ac
'/>"/>

SOURCE Azur Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Aoxing Pharmaceutical,Company, Inc. (OTC Bulletin Board: CAXG), which ... highly regulated narcotic,medicines and pain medication in China, ... fiscal 2008 ended September 30, 2007. China ... first quarter of fiscal 2008, a 33% sequential ...
... Convergence and New Opportunities, NEW BRUNSWICK, N.J., Nov. ... organizational changes to sharpen its,focus on opportunities outside its ... health care. These include the creation of a new,strategy ... The,changes are designed to accelerate growth for Johnson & ...
... 14 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... development and commercialization of novel drugs in the,therapeutic ... its financial results for the third quarter ended ... The net loss for the three months ended ...
Cached Biology Technology:China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 2China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 3China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 4China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 5Johnson & Johnson Announces Changes to Accelerate Growth 2Johnson & Johnson Announces Changes to Accelerate Growth 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 2Advanced Life Sciences Announces Third Quarter 2007 Financial Results 3Advanced Life Sciences Announces Third Quarter 2007 Financial Results 4Advanced Life Sciences Announces Third Quarter 2007 Financial Results 5Advanced Life Sciences Announces Third Quarter 2007 Financial Results 6Advanced Life Sciences Announces Third Quarter 2007 Financial Results 7Advanced Life Sciences Announces Third Quarter 2007 Financial Results 8Advanced Life Sciences Announces Third Quarter 2007 Financial Results 9
(Date:4/18/2014)... Peru found that 28 percent of the batches ... Many pills released the active ingredient too slowly. ... had no active ingredient at all. , ... Georgia Institute of Technology developed a sophisticated approach ... drugs and then characterize their chemical composition. The ...
(Date:4/18/2014)... URBANA, Ill. For the past 20 years, researchers ... of the research findings have suggested that soil organic ... or conventional tillage systems to no-till systems. However, there ... no-till systems in corn and soybean rotations without cover ... soil organic carbon stocks at the published rates. , ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... Cincinnati, OH, April 14, 2011 -- The number of couples ... often use assisted reproductive technologies, like in vitro fertilization (IVF), ... can also increase the risk of multiple pregnancies (i.e., twins ... one embryo. Twins and triplets are likely to be ...
... hormone known to inhibit aging can also protect kidneys against ... Scientists led by Dr. Makoto Kuro-o, associate professor of pathology, ... renal fibrosis a common complication of chronic kidney disease ... online in the Journal of Biological Chemistry . ...
... and economic security concerns have triggered interest in using algae-derived ... or any other biofuel source can require a ... smart about where we grow algae can drastically reduce how ... biofuel, while being water-wise, could also help meet congressionally mandated ...
Cached Biology News:New study finds stronger regulations of in vitro fertilization may save lives 2Anti-aging hormone Klotho inhibits renal fibrosis, cancer growth 2Study: Algae could replace 17 percent of US oil imports 2Study: Algae could replace 17 percent of US oil imports 3Study: Algae could replace 17 percent of US oil imports 4
...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Signets Xylene Resistant (X/R) Red System ... X/R Red Activator and X/R Red ... with alkaline phosphatase to produce red ... ,Kit Contains:, , Buffer, 100 ...
Human Cell Line Slides...
Biology Products: